CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 enrolled
Drug / intervention
Meningococcal vaccine GSK 134612 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01235975
NCT01235975Phase 3Completed
CompareCT.gov

Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older

GlaxoSmithKline·interventional·Posted Nov 8, 2010·Updated Aug 20, 2018

In Brief

A Phase 3 clinical trial evaluating Meningococcal vaccine GSK 134612 and MencevaxACWY TM for Infections, Meningococcal. Completed, enrolled 400 participants across 1 site.

Detailed Summary

This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesLebanon
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 8, 2010
Enrollment StartNov 30, 2010
Primary CompletionJul 29, 2011
Study CompletionAug 3, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.7 years ago

Interventions

Meningococcal vaccine GSK 134612biological

Intramuscular injection

MencevaxACWY TMbiological

Subcutaneous injection